La solution 5G SA Core de Mavenir, flexible et agile, permet à EOLO de fournir de manière rentable des services FWA à haut débit dans les zones difficiles à connecter à travers l’Italie RICHARDSON, Texas, 11 févr. 2025 (GLOBE NEWSWIRE) — Mavenir, le fournisseur d’infrastructures basées sur le cloud qui bâtit les réseaux de demain, […]
Continue ReadingStrategic partnership delivers future-proof, global payments capabilities for insurance carriers BOSTON, Feb. 11, 2025 (GLOBE NEWSWIRE) — Duck Creek Technologies, the global intelligent solutions provider defining the future of property and casualty (P&C) and general insurance, today announced a strategic partnership with Worldpay®, a global industry leader in payments technology and solutions. Worldpay’s global payments capabilities embedded […]
Continue ReadingSlovenian Nova Gorica and Italian Gorizia are coming together to write a new cultural chapter – one without borders. On 8 February 2025, Slovenia’s Cultural Holiday, the twin cities are hosting a spectacular all-day opening celebration. Under the title From Station to Station, the festivities will unfold across streets and squares, brought to life by […]
Continue ReadingLa ville slovène de Nova Gorica et la ville italienne de Gorizia s’unissent pour écrire un nouveau chapitre culturel qui transcende les frontières. Les villes jumelles transfrontalières organisent une célébration d’ouverture spectaculaire qui durera toute la journée du 8 février 2025, journée de la culture en Slovénie. Sous le titre From Station to Station (De gare en gare), les festivités se dérouleront dans les […]
Continue ReadingSlovenian Nova Gorica and Italian Gorizia are coming together to write a new cultural chapter – one without borders. On 8 February 2025, Slovenia’s Cultural Holiday, the twin cities are hosting a spectacular all-day opening celebration. Under the title From Station to Station, the festivities will unfold across streets and squares, brought to life by […]
Continue Reading– Advancing Phase 2 and Phase 3 trials of obexelimab, a unique CD-19 x FcγRIIb inhibitor of B cell function- -Topline results from Phase 2 Trial in Relapsing Multiple Sclerosis (MoonStone) expected in third quarter 2025- -Topline results from pivotal Phase 3 Trial in Immunoglobulin G4-Related Disease (INDIGO) expected year-end 2025- – Enrollment of Phase […]
Continue Reading